About the Company:
Apollo Hospitals was established in 1983 by Dr. Prathap C Reddy, renowned as the architect of modern healthcare in India. As the nation's first corporate hospital, Apollo Hospitals is acclaimed for pioneering the private healthcare revolution in the country. Apollo Hospitals has emerged as Asia's foremost integrated healthcare services provider and has a robust presence across the healthcare ecosystem, including Hospitals, Pharmacies, Primary Care & Diagnostic Clinics and several retail health models.
Apollo Hospitals was the first in India to launch the concept of Preventive Health Checks. From the date of inception in 1987 till date, over 20 Million health checks have been completed. They are the largest provider of Cardiology services in India. Apollo Hospitals has treated the largest number of cardiovascular cases with advanced cardiac interventional methods including 6 out of 9 MITRACLIP procedures
Apollo Hospitals Group is the only one in India to partner with Microsoft's AI Network for AI-powered Cardiovascular Disease Risk Score API. The API enables physicians to predict the risk of CVDs at least 5 to 7 years in advance in patients. Over 200,000 patients have been screened till date. Apollo Hospitals, in partnership with Abbott, has also set up India's first National Cardiac Registry.
QoQ & YoY Performance:
India’s leading health care facilities company has declared the results for the third quarter of the fiscal year ending March 2020.
- QoQ Performance: Consolidated Net revenue of the company reported to Rs.291174 Lakhs rose by almost 2.50% in the December quarter of FY20. Total expenditure (excluding interest and depreciation expenses) stood at Rs.248172 Lakhs is increased by 2.24%. EBITDA numbers increased by 5.44%.
- YoY Performance: The Company has reported a growth of 16.70% in sales/revenue while expenditure (excluding interest and depreciation expenses) of the company has witnessed an uptake by 11.99%. EBITDA numbers also soar by 50.78%.
- The profitability of the company: Profit after tax of the company resulted in a gain of Rs.8995 Lakhs increased by 8.24% QoQ and increased by 80.37% YoY.
- The Board of Directors declared an interim dividend of Rs.3.25 per share (65% of the face value of Rs.5/- per share) for the financial year ending 3l March 2020, on the paid-up equity shares, out of the profits of the Company.
As per Lokesh Sethia, SEBI Registered Research Analyst, the Apollo Hospital is currently trading at Rs.1700 per share, the company’s combined financial performance reflecting very good strength in the income statement. So it seems like stock price can be touch 1930 levels in this quarter. So our recommendation for Apollo Hospital is to buy.
This is for the sole purpose to provide client(s) information of EQUITY GLOBAL RESEARCH (EG) and not to interpret as investment advice. It is also not to consider as an offer or solicitation for the purchase and sale of any financial instrument. Any action taken based on given information contained herein is your responsibility alone. EQUITY GLOBAL RESEARCH and its subsidiaries/employees/associates will not be liable in any manner for the consequences of such action taken by you. The due diligence we have exercised after checking the correctness and authenticity of the information contained in this recommendation. In case of any inadvertent error in the used information to make this recommendation or action taken based on information the EQUITY GLOBAL RESEARCH or any of its subsidiary or associate or employee shall not be liable in any way responsible for any loss or damage. The recommendations provided here based on either Technical Analysis, Fundamental Analysis or both. EQUITY GLOBAL RESEARCH has issued this document on information obtained from sources it believes to be reliable but not independently verified; Also, the EQUITY GLOBAL RESEARCH makes no promises, guarantee, or accepts no responsibility as to its accuracy or completeness. The opinions contained within the report based on publicly available information at the time of publication and subject to change without any intimation. Any piece of information and disclosure provided herein is in summary form and has been prepared for informational purposes. The recommendations are only valid for the day of the issued report however, trading trends, volumes might vary substantially on a daily basis, and recommendations may change accordingly. The information provided herein is entirely confidential. Any misuse, distribution, modification, copying, or forwarding by any person strictly prohibited. The information provided herein does not constitute a solicitation or offer to buy or sell any security or other financial instruments. The current performance may be unaudited. Past performance does not guarantee future returns. There can be no assurance that investment will achieve any targeted rates of return, and there is no guarantee against the loss of your entire investment.